BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:L-selectin/CD62L: not just a lymph node homing receptor on T-cells
  - Professor Ann Ager\; Professor of Cellular Immunity and Immunotherapy\,
  University of Cardiff
DTSTART:20210728T140000Z
DTEND:20210728T150000Z
UID:TALK158584@talks.cam.ac.uk
CONTACT:Bobbie Claxton
DESCRIPTION:Ann Ager is Professor of Cellular Immunity and Immunotherapy i
 n the Division of Infection and Immunity\, School of Medicine and a member
  of the Systems Immunity Research Institute\, Cardiff University\, Cardiff
 \, UK.\n\nThe Ager lab studies how T lymphocytes move around the body to p
 rotect against infection\, control cancer growth and contribute to neurode
 generation such as in Alzheimer's disease.  A major focus has been the reg
 ulation of L-selectin/CD62L expression by T lymphocytes and its impact on 
 physiological and pathological T-cell recruitment from the bloodstream int
 o tissues via specialised high endothelial venule (HEV) and inflamed blood
  vessels. Recent studies have revealed an essential role for L-selectin in
  the recruitment of killer T cells into flu-infected lungs for virus clear
 ance. Current studies are exploring pharmacological and genetic approaches
  to boost L-selectin expression on T lymphocytes to help killer T cells fi
 nd and destroy viruses. Studies of T-cell homing to cancerous tissues usin
 g preclinical mouse models and clinical cancers have revealed a critical r
 ole for L-selectin on T cells and neogenesis of cancer-associated HEV bloo
 d vessels in limiting cancer progression. Moreover\, these studies have re
 vealed a mechanism of improving the efficacy cancer-killing T lymphocytes\
 , such as CAR-T cells\, by manipulating expression of L-selectin which is 
 currently being tested in clinical settings. \n\nAnn gained a PhD from Cam
 bridge University studying inflammatory responses in vascular endothelial 
 cells. \n\nAfter training in microvascular biology with Professor Judah Fo
 lkman in Boston\, she began her life-long interests in high endothelial ve
 nule (HEV) blood vessels and T-cell trafficking as a postdoctoral fellow w
 ith Professor Bill Ford at the University of Manchester.  \n\nAnn gained a
 n MRC Senior Fellowship before moving to a PI position at the MRC National
  Institute for Medical Research in London where she began working on L-sel
 ectin/CD62L.  Ann moved to Cardiff University as Reader and was awarded a 
 personal chair in 2018.  Since moving to Cardiff\, Ann’s research has fo
 cussed on T-cell trafficking in virus infection\, cancer and\, more recent
 ly\, in Alzheimer’s disease.\n\nAs Chair Forum and a Trustee of the Brit
 ish Society for Immunology (BSI) and Council member of the International U
 nion of Immunological Societies (IUIS)\, Ann is an advocate for Immunology
  to governments and other policy makers. \n\n\nJoin live using this link -
  https://zoom.us/j/98778776637 
LOCATION:Online via zoom
END:VEVENT
END:VCALENDAR